Minimally Invasive Surgery

Aulea Medical manufactures the Veloxion all-in-one system, a single-use, integrated platform for benign prostatic hyperplasia (BPH) treatment via transurethral resection of the prostate (TURP). The system combines fluid management, video imaging, and radiofrequency energy generation in a single console to streamline urology workflows. Key clinical innovations include automated intravesical pressure monitoring and control, motorized plasma cutting technology, multi-directional resection capability, and immediate tissue evacuation to maintain visualization. The Veloxion is designed to reduce BPH treatment time to approximately 20 minutes compared to standard TURP (60 minutes), enable same-day procedures in ambulatory surgery centers for prostate glands ranging 30–200g, and eliminate infection risk and cross-contamination through single-use endoscopic devices. The system requires minimal setup and teardown, reducing procedure time and cost of ownership. Aulea targets urology departments, ambulatory surgery centers, and specialty urology practices. The company emphasizes safety (pressure management to prevent bladder perforation, sterile single-use design), simplicity (plug-and-play console, automated fluid evacuation), and procedural efficiency. Manufacturing capabilities include single-use device fabrication and integrated RF energy generation systems.

FAGA Medical is a Brazilian manufacturer of medical-surgical equipment and instruments specializing in lipoaspirative and cosmetic surgical solutions. The company develops and manufactures electromedical equipment, reusable surgical instruments, and disposable consumables with a focus on precision, safety, and cost-effectiveness. Core product lines include vibratory liposuction systems (VIBROFIT®), ultrasonic-assisted fat extraction equipment (SAFER), surgical irrigators (INFlow), surgical cannulas manufactured from 316L stainless steel, fat transfer devices, and surgical support materials including drainage systems, collection bottles, and specialized surgical kits. Products are designed in partnership with clinical professionals to address real-world surgical needs. FAGA Medical maintains strategic partnerships with technology partners in Germany, Switzerland, France, and the United States. The company holds certifications including ANVISA (Brazilian regulatory approval), FDA, ISO 9001, and ISO 13485, demonstrating compliance with international quality and medical device standards. Manufacturing encompasses equipment design, precision instrumentation, sterilization-compatible materials, and quality control throughout production. The company serves surgical centers, hospitals, and cosmetic medical practices with emphasis on ergonomics, durability, and procedural efficiency.

Innova Vascular, Inc. is a medical device company headquartered in Irvine, California, specializing in minimally invasive solutions for treating vascular thromboembolism and peripheral vascular disease. The company develops and commercializes thrombectomy devices targeting acute pulmonary embolism and peripheral arterial occlusions. Core product line: the Laguna Thrombectomy System, which comprises the Laguna Clot Retriever™ System and Malibu Aspiration Catheter™ System. Both devices received FDA 510(k) clearance in June 2023 for use in the peripheral vasculature. Early commercial deployment has been reported at UCLA Medical Center (Los Angeles) and Providence St. Joseph (Orange, California) as of February 2024. The company is actively enrolling clinical sites for the TRUST (Treating Pulmonary Embolism With Laguna Thrombectomy System) study to evaluate the system's safety and efficacy in pulmonary embolism treatment. Founded by Dr. Sanjay Shrivastava, who brings over 20 years of medical device development and commercialization experience from senior roles at Johnson & Johnson, Medtronic, BTG plc, and Covidien/ev3. The leadership team includes board members with expertise in orthopedics, business development, and venture capital, and commercial leadership includes VP of Sales Paul Mullen and Commercial Advisor John Zehren. Regulatory: FDA 510(k) cleared. Founder holds 30+ issued US patents and numerous international patents in medical device design and materials. Markets served: interventional cardiology, peripheral vascular intervention, and acute vascular disease management at teaching hospitals and regional medical centers.

Tecomet, Inc. is a global precision contract manufacturer founded in 1963 and headquartered in Woburn, Massachusetts, serving the medical device, orthopedic, and minimally invasive surgical markets. With 2,000+ employees across 14 manufacturing campuses in five countries, Tecomet generates approximately $678.9 million in annual revenue. The company is recognized as the world's largest orthopedic contract manufacturer, delivering end-to-end manufacturing solutions from design prototyping through full-scale production. Tecomet specializes in complex, high-precision products utilizing proprietary technologies including photochemical etching, precision machining, additive manufacturing, net shape forging, casting, laser and electron beam welding, and robotic finishing. Core offerings include orthopedic implants (hip, knee, shoulder, spine, trauma & extremities), precision surgical instruments, minimally invasive surgical components, and specialized cases and trays. The company provides comprehensive services encompassing innovation and design consulting, rapid prototyping, packaging and sterile cleanroom assembly, and full production support. Its collaborative approach and rigorous quality standards make it a preferred partner for leading medical device OEMs seeking scalable, innovative manufacturing solutions for orthopedic and surgical device products.

Addition Technology Inc is an FDA-approved ophthalmic device manufacturer established in 2001 and headquartered in Lombard, Illinois. The company specializes in Intacs® Corneal Implants, the only FDA-approved intracorneal segments designed for minimally invasive surgical treatment of myopia and keratoconus. Operating as part of AJL Ophthalmic (since 2013), Addition Technology manufactures medical devices in ISO 13485 certified facilities compliant with FDA 21 CFR 820 and the Medical Device Directive (MDD) 93/42/EEC. The company collaborates with recognized ophthalmologists, universities, and technological centers to develop innovative products that improve patient vision outcomes and help defer or eliminate the need for corneal transplants in patients with keratoconus experiencing contact lens intolerance.

TAS Medical, Inc. is a surgical device manufacturer specializing in soft tissue approximation and abdominal wall closure solutions. The company has developed the ZipStrap system, a surgical-grade device designed to facilitate soft tissue approximation across open, laparoscopic, and robotic surgical procedures in general surgery. The ZipStrap represents an innovation in wound closure and tissue approximation technology, offering surgeons an alternative approach to traditional closure methods. The company serves the general surgery market, including surgeons performing open, minimally invasive laparoscopic, and robotic-assisted procedures. TAS Medical is based in Windermere, Florida. The company website indicates regulatory clearance documentation is available via their Instruction for Use (IFU) page, suggesting FDA or equivalent regulatory approval for the ZipStrap device. The organization engages with multiple stakeholder groups including physicians, advanced practice providers, healthcare administrators, and industry representatives.

SurGenTec is a privately held medical device manufacturer specializing in minimally invasive orthopedic and neurosurgical spine solutions. The company develops and markets a comprehensive portfolio of bone graft delivery systems, synthetic biologics, sacroiliac joint fusion implants, and spine stabilization hardware. Core product lines include the GraftGun® precision delivery system, OsteoFlo® bone void fillers (HydroFiber, HydroPutty, NanoPutty), TILINK® SI joint and lateral fusion systems, ION-C™ cervical stabilization, ALARA® Access Needle, and Ossify® cortical fiber grafts. SurGenTec's devices feature advanced surface technologies and are FDA-cleared for use across cervical, thoracic, and lumbar spine applications, including trauma, tumor, osteomyelitis, and degenerative indications. The company serves both domestic and international surgical markets through direct sales and distributor partnerships.

HealthTronics is a specialized urology equipment and service provider serving over 1,500 physicians and 2,000 healthcare facilities nationwide. The company specializes in lithotripsy (shockwave), laser, and ureteroscopy solutions for kidney stone disease management. HealthTronics offers a comprehensive stone management platform including extracorporeal shock wave lithotripsy (ESWL) systems, laser lithotripsy equipment, single-use ureteroscopes, and consumables for ureteroscopic procedures. The company operates under a physician investment model, providing joint venture and partnership solutions to urologists and hospital systems seeking capital-efficient kidney stone treatment programs. Core service capabilities include equipment rental, maintenance, repair, and technical support through field engineers deployed nationally. HealthTronics emphasizes operational management of medical technology, quality assurance, compliance support, and process optimization. The company positions itself as both a product supplier and operational solutions provider, enabling practices and facilities to improve financial performance, patient satisfaction, and clinical focus while reducing system costs. Customers include independent urology practices, health systems, and ASCs requiring reliable access to stone management equipment with integrated technical and administrative support.

Highridge Medical is a global medical device company specializing in innovative spinal solutions and motion preservation technologies. Established in 2024 following H.I.G. Capital's acquisition of the Spine and EBI businesses from ZimVie, the company develops comprehensive spine surgical portfolios including cervical and lumbar disc replacement systems, deformity fixation platforms, interbody fusion devices, and vertebral body tethering systems. Highridge's product line features the Mobi-C® Cervical Disc, the upcoming activL® Lumbar Disc (launching July 2025), the Vital™ Navigation System for open and minimally invasive procedures, and additional fixation and fusion solutions. The company emphasizes surgeon-driven design, clinical research and development, and medical education to advance spine care outcomes. Leadership includes Executive Chairman Eric Major and CEO Rebecca Whitney, with a commitment to advancing patient mobility and strength through accountable, compassionate partnerships with healthcare providers.

Signum Surgical is an Irish medtech company specializing in minimally invasive surgical solutions for colorectal diseases, particularly anal fistula treatment. Founded in 2014 and based in Galway, the company develops the BioHealx implant—a helical, barbed, bioabsorbable implant designed to close fistula tracts through tissue apposition while preserving anal sphincter function and continence. The implant is delivered via a single-use, pre-loaded disposable device that rotates the helical structure into soft tissue at the fistula source, eliminating exposure to the ano-rectal canal. Signum Surgical addresses a significant clinical need: approximately 90,000 annual surgical procedures are performed in the U.S. alone for anal fistula treatment, yet existing options carry high recurrence rates, healing complications, and risk of permanent incontinence. The BioHealx approach offers FDA-cleared technology designed to optimize outcomes, promote primary healing, and reduce recurrence—all within a single procedure—thereby improving patient quality of life and surgical efficacy.

Focalyx is a MedTech company specializing in precision diagnosis and treatment of prostate cancer through AI-driven software and minimally invasive procedural guidance. The Focalyx Fusion platform provides computer-assisted surgical planning and real-time intraoperative guidance for focal prostate therapy, enabling targeted ablation of cancerous lesions while preserving healthy prostate tissue and function. The platform combines advanced imaging analysis with GPS-like navigation to deliver office-based, outpatient prostate cancer treatment with minimal hospitalization, fast recovery, and improved preservation of urinary and sexual function. Clinical outcomes demonstrate 86% cancer-free status at 5 years with 95% urinary improvement and 88% erectile retention rates across 6,000+ procedures performed globally.

PLU Ophthalmic is a US-based medical device company developing next-generation glaucoma surgical technology. The company focuses on advanced glaucoma care solutions that bridge the current clinical gap between traditional high-efficacy but high-risk procedures (trabeculectomy) and minimally invasive glaucoma surgery (MIGS) techniques that offer superior safety but limited efficacy. PLU Ophthalmic's proprietary technology employs precise micro-excision methodology to deliver implant-free glaucoma surgery with superior intraocular pressure reduction, enhanced safety profile, and minimal learning curve compared to existing MIGS platforms. The technology addresses a significant clinical need: glaucoma is the second leading cause of blindness globally, affecting approximately 80,000 people worldwide with 3 million cases in the US and a projected economic burden of $12 billion by 2032 and $17.3 billion by 2050. The company's solution targets ophthalmologists and glaucoma specialists seeking to improve surgical efficacy while reducing procedural risk and post-operative complications. PLU Ophthalmic emphasizes simplified patient management, enhanced patient outcomes, and improved OR productivity through shorter surgical times and reduced post-operative care requirements. The platform is designed to outperform current MIGS offerings while maintaining a safety advantage over traditional trabeculectomy, positioning it as a transformative approach in glaucoma surgical care.

Distalmotion SA is a Switzerland-headquartered medical device company founded in 2012, specializing in robotic-assisted surgical systems designed to expand access to minimally invasive surgery. The company develops and markets the DEXTER® Robotic Surgery System, a compact, integrated platform engineered to simplify robotic surgical workflows and enable deployment across diverse operating room environments, including outpatient facilities. DEXTER is designed for compatibility with existing hospital infrastructure and surgeon preferences, reducing barriers to robotics adoption compared to larger, more complex systems. The system targets general surgeons, surgical specialists, and hospital systems seeking to establish or expand robotic surgery capabilities without substantial operational disruption. The company operates globally with a multinational team based in Lausanne, Switzerland. While specific regulatory certifications (FDA clearance status, 510(k), CE marking) are not explicitly detailed in the fetched content, the company's positioning as a commercial medical device provider suggests appropriate regulatory compliance. DEXTER is positioned as a user-centric alternative to incumbent robotic platforms, emphasizing surgeon ergonomics, workflow integration, and institutional scalability. The company serves hospitals, healthcare providers, and surgeons across multiple care settings. Manufacturing and regulatory credentials require verification via additional sources.

CooperSurgical is a global leader in women's health and fertility solutions, headquartered in Trumbull, Connecticut. As a key business unit of The Cooper Companies, Inc., the company develops and distributes innovative medical devices, surgical instruments, and diagnostic tools for reproductive care, obstetrics, gynecology, and general women's health. Founded in 1990, CooperSurgical operates a 214,000-square-foot manufacturing and distribution facility in Connecticut and maintains a presence across North America, Europe, Asia-Pacific, and the Middle East. The company offers over 600 products served through multiple trusted brands, addressing healthcare needs from contraception and fertility through labor and delivery. With manufacturing expertise in molecular diagnostics, embryology systems, advanced hysteroscopy, and minimally invasive surgical technologies, CooperSurgical serves healthcare providers through direct sales, distribution networks, and comprehensive support services including preventative maintenance, product training, and spare parts availability. The company employs over 3,000 people and generates annual revenue exceeding $680 million.

HistoSonics, Inc. is a medical device manufacturer specializing in histotripsy, a proprietary non-invasive ultrasound technology that mechanically destroys targeted tissue without surgery, heat, or incisions. Founded in 2009 by University of Michigan experts, the company has developed the Edison system—an FDA-approved, robotic, image-guided platform for the non-invasive mechanical destruction of liver tumors. The Edison system uses focused ultrasound to create a controlled bubble cloud that liquefies unwanted tissue in real-time at the sub-cellular level. With over 100 systems deployed globally and significant insurance coverage expansion (7 million BCBS Highmark members), HistoSonics is actively expanding clinical applications beyond liver oncology to kidneys and pancreas through ongoing HOPE4KIDNEY and GANNON clinical trials. The company serves interventional radiologists, surgical oncologists, hepatologists, and transplant surgeons, positioning histotripsy as a tissue-sparing alternative to traditional surgical and thermal ablation approaches for tumor treatment.

STARmed America, Inc. is the U.S. subsidiary of South Korean medical device manufacturer STARmed Co., Ltd., established in October 2023. Based in Los Angeles, the company specializes in FDA-cleared radiofrequency ablation (RFA) systems and electrodes for minimally invasive treatment of soft tissue conditions. STARmed offers four RFA generator systems and over ten types of electrodes, including the pioneering thyroid-dedicated RF electrode first developed in 2004. Products are designed for percutaneous and endoluminal ablation applications across thyroid, liver, kidney, lung, bone, biliary, pancreatic, and uterine fibroid conditions. The company currently supports over 120 medical facilities across 36 U.S. states and has trained more than 300 physicians. STARmed provides comprehensive program support including hands-on training, clinical case assistance, reimbursement guidance, and marketing support, with 96% physician satisfaction rates.

Chase Medical is an ISO 13485 certified medical device manufacturer and worldwide distributor specializing in innovative technologies for advanced cardiovascular surgery. The company focuses on beating heart/off-pump CABG (Coronary Artery Bypass Graft) procedures and Surgical Ventricular Restoration (SVR). Chase Medical's product portfolio includes vacuum-assisted stabilization systems, atraumatic intracoronary shunts, surgical arms with reusable and disposable attachments, and the Mannequin system for left ventricular reshaping and restoration in ischemic heart failure patients. With over 25 years of experience and a reputation for high-quality, state-of-the-art devices, Chase Medical serves cardiac surgeons globally with both disposable and reusable surgical solutions for on-pump, off-pump, and pump-assist procedures.

Promaxo is a MedTech company specializing in compact, single-sided portable MRI systems and AI-driven technologies for interventional imaging and image-guided procedures. The company's flagship product is an office-based MRI platform that received FDA clearance in March 2021, enabling real-time MR-guided biopsies and cancer treatment in ambulatory settings without requiring dedicated MRI suites. Promaxo's system is designed for urologists and hospitals targeting prostate cancer diagnosis and treatment, featuring AI-driven tissue characterization with reported 77% cancer detection rates and 33% improvement in detecting clinically significant cancers versus standard of care. The system requires minimal facility upgrades and integrates seamlessly into existing clinical workflows, allowing concurrent clinic operations and interventional procedures. Founded in 2016 and backed by strategic investors including MicroPort and Zepp Health, Promaxo holds over 200 patents and is expanding applications to breast oncology and orthopedics. The company is led by CEO and Chairman Amit Vohra.

Tegra Medical is a global contract manufacturer specializing in end-to-end production of medical devices. Headquartered in Franklin, Massachusetts, with manufacturing facilities across the United States, Costa Rica, Switzerland, and Asia, the company employs over 1,000 people. Tegra Medical delivers comprehensive manufacturing solutions including design, prototyping, precision production, assembly, packaging, and sterilization for complex metal and plastic components. The company serves multiple therapeutic areas including oncology, orthopedics, cardiology, minimally invasive surgery, ophthalmic, women's health, drug delivery, and robotic-assisted surgery applications. Advanced manufacturing capabilities include Swiss machining, multi-axis milling, injection molding, wire grinding, and precision finishing. Tegra Medical maintains ISO 13485 certification and FDA registration, supported by rigorous quality management systems. The company also operates Quick Wire & Tubing, an e-commerce platform offering in-stock and custom wire, tubing, and secondary processing services for medical device development and prototyping.

Starr Frame LLC manufactures specialized minimally invasive surgical systems for orthopedic trauma, specifically designed for closed reduction of pelvic ring and acetabular fractures. The company's flagship products—the Starr Frame Orion®, Starr Frame®, and Reinert Reduction Instruments—enable surgeons to apply consistent, controlled reduction forces in a step-wise manner, facilitating precise deformity correction with reduced surgical time and minimized wound complications. These fluoroscopy-compatible systems feature radiolucent carbon fiber components and are engineered for percutaneous application, significantly shortening patient recovery periods compared to traditional open reduction methods. Starr Frame serves orthopedic trauma surgeons and trauma centers globally.

Fziomed, Inc. is a global leader in surgical adhesion prevention, founded in 1996 and headquartered in San Luis Obispo, California. The company specializes in developing, manufacturing, and commercializing surgical biomaterials designed to prevent postsurgical adhesions—a common complication following surgical procedures. Fziomed's products utilize proprietary dual-polymer gel technology to create clear, absorbable formulations that provide temporary tissue separation during the healing process, significantly reducing adhesion formation. The company's flagship product, Oxiplex® gel, received FDA De Novo classification and marketing authorization in July 2025 for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Fziomed's adhesion barrier products are marketed in over 70 countries and have been utilized in nearly 1 million procedures worldwide since 2002. The product portfolio addresses multiple surgical disciplines including spine surgery, tendon and peripheral nerve procedures, intrauterine surgery, and abdominal/pelvic procedures. With approximately 59 employees, Fziomed maintains full control over both manufacturing and commercialization of its innovative surgical solutions.

GT Metabolic Solutions is a medical device company specializing in magnetic compression anastomosis technologies for minimally invasive bariatric and metabolic surgery. Founded in May 2020 by Dr. Michel Gagner and Thierry Thaure, the company holds a portfolio of over 17 patents focused on advancing surgical techniques. The flagship MagDI™ System represents an innovative incisionless, sutureless, and staple-free surgical approach using magnetic technology to create anastomosis, particularly for side-to-side duodeno-ileal procedures. The system received FDA De Novo marketing authorization in July 2024, with subsequent 510(k) clearances for second-generation magnets in 2024 and 2025. Clinical evidence demonstrates the MagDI™ System enables durable weight loss and improved glycemic control in obese patients with or without type 2 diabetes. The technology eliminates foreign material implantation, supporting natural tissue healing and enabling outpatient surgical delivery. GT Metabolic is actively advancing clinical trials in North America and Europe, positioning magnetic surgery as a next-generation frontier in minimally invasive bariatric and metabolic procedures.

Voom Medical Devices is an orthopedic medical device company specializing in minimally invasive bunion surgery (MIBS) solutions. Founded in 2017 by Dr. Neal Blitz, the company has raised $41.21 million to advance surgical innovation. The flagship offering is the Bunionplasty® 360 Repair™ procedure, which utilizes the proprietary Revcon™ Anchor—a patented non-compression, single-screw system with dual-zone technology for bunion correction. The system is designed as a fusion-free approach that preserves range of motion, reduces postoperative pain, and accelerates patient recovery. Voom provides comprehensive surgeon training programs and a patient engagement platform (Bunionplasty.com) to support clinical adoption and patient education. The company targets orthopedic surgeons and surgical centers seeking to offer advanced minimally invasive foot and ankle procedures with improved clinical outcomes.

Otsuka Medical Devices Co., Ltd. (OMD) is a Japanese medical device manufacturer specializing in minimally invasive endovascular therapies and innovative treatment solutions. Operating from Tokyo with the HARUMI Technology Center serving as a global R&D and training hub, OMD develops products for high-need disease areas including cardiovascular and oncology applications. The company combines Otsuka Group's pharmaceutical expertise with advanced device technology to address treatment-resistant conditions and diseases lacking effective therapeutic options. ISO 13485:2016 certified for vascular stents and ultrasound renal denervation systems. Key product platforms include the Paradise System for ultrasound-guided renal denervation, BioMimics 3D peripheral artery stent for complex vascular anatomy, and Tron FX thrombectomy device for acute vascular interventions. OMD maintains a global research and development infrastructure to advance endovascular therapy, apheresis technologies, and photodynamic therapy approaches.

Caldera Medical is a U.S.-based medical device manufacturer headquartered in Westlake Village, California, specializing in minimally invasive surgical solutions for women's pelvic health. Founded in 2002, the company develops and markets innovative products for stress urinary incontinence (SUI), pelvic organ prolapse (POP), and hysteroscopic tissue removal. The company's product portfolio includes the Desara® Family for SUI treatment, the Vertessa® Family for POP repair, the Benesta Family for hysteroscopic procedures, and the Luminelle system launched in 2024 for advanced gynecological applications. Recognized as the fastest-growing women's health company for three consecutive years, Caldera Medical emphasizes surgeon collaboration, physician training, and clinical support. The company is committed to improving patient outcomes through durable, effective minimally invasive treatments while supporting a global humanitarian program aimed at reaching one million women with pelvic health education and treatment by 2027.

Baird Medical is a pioneering medical technology company established in 2012, specializing in advanced minimally invasive microwave ablation (MWA) technology for thyroid, breast, liver, and uterine fibroid treatment. As the first company in China to receive a Class III registration certificate for microwave ablation of thyroid nodules, Baird represents the cutting edge of thermal ablation innovation. The company manufactures proprietary microwave ablation needles and therapy apparatus systems designed for both benign nodule treatment and malignant thyroid cancer management, including recurrent disease intervention. Baird is committed to delivering superior patient outcomes through reduced scarring, faster recovery times, and minimally invasive alternatives to traditional surgical approaches, supported by comprehensive physician education and clinical training programs.

TYBR Health is a Houston-based medtech company founded in 2020, specializing in regenerative medicine and post-operative recovery solutions for orthopedic surgery. The company addresses a critical clinical gap: while surgical procedures for tendon and ligament repair are often technically successful, post-surgical tissue scarring and adhesions frequently result in long-term functional limitations and mobility restrictions affecting patient outcomes. TYBR Health's flagship product, B3 GEL™, is a naturally derived, flowable bio-gel barrier designed to be applied intraoperatively to coat tendons, ligaments, and surrounding tissues during minimally invasive procedures. The hydrogel creates a protective barrier that mitigates internal scarring and tissue tethering, supporting optimal healing and functional recovery. The solution targets the approximately 120,000 annual tendon procedures performed in the United States, where up to 40% of patients currently face lifelong mobility limitations despite surgical success.

Biofusion Medical, operating under the SI-Restore® brand, specializes in sacroiliac joint (SI) fixation systems for minimally invasive spinal surgery. The company designs and manufactures the SI-Restore® Sacroiliac Joint Fixation System, featuring proprietary Nano BioBlast™ surface treatment technology. This advanced surface roughening process creates an ideal macro and micro-porous texture optimized for bone attraction, adhesion, and osseointegration, enhancing long-term bony on-growth and implant stability. The technology utilizes biocompatible hydroxyapatite media without residual contamination or coatings that could delaminate. SI-Restore® combines integrated implant design with simplified, patented instrumentation to reduce procedural steps and complexity, targeting improved surgical ease and reduced patient complications. The system is designed for surgeons performing minimally invasive sacroiliac joint fusion procedures. Products are protected under US design patents (D857,897 S and D857,898 S). The company markets to surgeons, distributors, and healthcare facilities focused on spine surgery and orthopedic solutions. SI-Restore® represents Biofusion Medical's focused portfolio in sacroiliac joint solutions, with emphasis on implant material science and surgical technique optimization.

Altaviz, LLC is a medical device innovation and design firm specializing in advanced drug delivery systems and ophthalmic solutions. Founded in 2012 and based in Irvine, California, the company develops proprietary platform technologies for the medical device, pharmaceutical, and biotechnology sectors. Altaviz offers modular framework solutions including autoinjectors, fluid injectors, gas injectors, and implant delivery systems—all designed for rapid customization to address specific client engineering challenges. The company provides comprehensive services spanning concept development, product engineering, technology transfer, and post-market support. A key innovation focus is medical-grade compressed gas technology for precision drug delivery and therapy applications. Altaviz serves startups through established firms, combining scalable manufacturing expertise with high-performance design to enhance patient safety and clinical outcomes.

Team Technologies, Inc. (rebranding as Cordica Medical as of January 2026) is a comprehensive medical device manufacturer and contract development and manufacturing organization (CDMO) headquartered in Knoxville, Tennessee. The company operates across multiple therapeutic and product categories, serving the diagnostic, surgical, and therapeutic markets with proprietary and contract manufacturing capabilities. Core product lines include: interventional cardiology and neurovascular catheter-based devices; in vitro diagnostic (IVD) testing and lateral flow assays; wearable patient monitoring sensors; advanced wound care products; infection control and PPE solutions (including privacy curtains, disposable apparel, and accessory products); pharmaceutical delivery and dosing systems; patient handling and mobility solutions; and dental/oral care products (toothbrushes, prophy angles, prophylaxis supplies). Manufacturing capabilities span product design and rapid prototyping, catheter extrusion and assembly, precision medical tubing, injection and blow molding, textile converting, RF welding, advanced bristling and tufting, wet and dry chemistry formulation, sewing and textile processing, and value-added customization. The company operates under ISO 13485 and FDA-regulated guidelines. U.S.-based manufacturing and supply chain operations support medical device OEMs and diagnostic companies from concept through commercialization. Specialty product brands include ICP Medical (privacy curtains/PPE), Rapid Refresh, Protexer, Bootie Butler, Topi-CLICK dosing applicators, AllPro dental supplies, PDS and PHB toothbrushes, and Prophy Perfect prophy angles.

PAJUNK® GmbH is a family-owned German medical technology manufacturer founded in 1965, specializing in innovative devices for regional anesthesia, pain management, neurology, biopsy, and minimally invasive surgery. Based in Geisingen, Baden-Württemberg, the company operates manufacturing facilities in Germany and the USA with subsidiaries across Europe and North America. With approximately 700 employees, PAJUNK® exports its comprehensive portfolio to over 100 countries through approximately 150 distributors. The company's core product range includes atraumatic spinal needles (Sprotte®), peripheral nerve block needles (SonoPlex® II), peripheral catheter kits (Sonolong SoftSecure, E-Cath® II), cannulas, catheters, and specialized connectors (NRFit®). PAJUNK® emphasizes user-focused innovation, patient safety, advanced safety standards, and modern production techniques. The company continues to invest in product development and clinical education, celebrating 60 years of market leadership in regional anesthesia and minimally invasive surgical devices.

Spinal Elements is a Carlsbad-based medical device company founded in 2004 that develops innovative, proprietary spine surgery technologies for minimally invasive procedures. The company specializes in advanced interbody solutions, metal-free fixation devices, and biologics for TLIF (transforaminal lumbar interbody fusion), ALIF (anterior lumbar interbody fusion), and posterior fixation applications. Their product portfolio includes the Ventana interbody system (available in lumbar and cervical configurations with 3D-printed options), the Luna TLIF portfolio, the Karma metal-free fixation system, the Sapphire X cervical plate system, and comprehensive core and biologics solutions. Spinal Elements operates as a market leader in commercializing spine surgery solutions through proprietary technologies, strategic distributor relationships, and surgeon partnerships. The company manufactures devices for hospital and ambulatory surgery center environments. Multiple products have received FDA 510(k) clearance, including recent clearances for the Ventana ALIF System and Sapphire X expansions. Spinal Elements has achieved notable contracts including a Vizient Innovative Technology Contract for the Karma Fixation System, demonstrating acceptance within major healthcare provider networks. The company maintains a surgeon-centric approach, collaborating with clinical experts to develop patient-first procedural solutions addressing the fastest-growing segments of the spine surgery market.

SigmaPro Engineering and Manufacturing is a Texas-based precision injection molding specialist serving medical device OEMs and Tier 1 suppliers. The company manufactures complex plastic components for minimally invasive surgical devices, drug delivery systems, diagnostic and analytical consumables, and optical/wearable medical assemblies. SigmaPro operates a 12,000 sq. ft. ISO 13485 and ISO 9001-certified facility in Fort Worth with Class 8 cleanroom capabilities for molding, assembly, and packaging. The facility integrates in-house tooling maintenance, coordinate measuring machines (CMM), optical inspection systems, and real-time process data monitoring to achieve micron-level dimensional tolerances (±4 microns) and validated production. The company is FDA-registered and maintains MDR compliance alignment. Services include design for manufacturability (DFM) consultation, tooling engineering, process validation, and scalable high-volume production. SigmaPro serves North American and European medical technology markets with emphasis on biocompatibility verification and regulatory documentation support for complex, high-precision plastic components.

Companion Spine is a spine care technology company focused on interventional therapies and minimally invasive solutions for degenerative disc disease, spinal stenosis, injury-related pain, and general back pain. The company develops and provides diagnostic technologies, pain management interventions, minimally invasive surgical tools, and implantable devices designed to preserve motion, respect natural anatomy, and avoid unnecessary permanent interventions. Their product portfolio includes recent acquisitions such as Coflex® and other devices from Xtant™. All Companion Spine technologies and therapies are designed for outpatient delivery in comfortable, discreet settings, emphasizing proactive, ongoing spine care that minimizes disruption to patient quality of life. The company positions itself as a provider of reversible, motion-preserving treatments delivered through percutaneous or minimally invasive surgical procedures, with a clinical approach that prioritizes early detection and conservative treatment before advanced surgical intervention becomes necessary.

Claria Medical develops the Claria System, an intelligent surgical platform designed for safe, minimally-invasive hysterectomy and related gynecological procedures. The system enables extraction of enlarged uteri using a vaginal approach without mini-laparotomy, addressing key clinical challenges in current hysterectomy techniques: container breach risks (potential for hidden cancer spread or bowel injury), significant abdominal scarring, and variable procedure times. The Claria System features redundant safety mechanisms for breach-resistant tissue containment, integrated lighting and blade technology within a large-bore handpiece for rapid extraction of large tissue volumes, and simplified handling to reduce procedural variability. The company has received prestigious National Science Foundation (NSF) and National Institute of Health (NIH) grants for product development. The platform is supported by published clinical evidence, including case reports from international surgical centers (Sydney Women's Endosurgery Centre, Hospital Angeles Morelia), a 30-surgeon usability study, and microbiological studies validating container integrity. Claria Medical targets gynecological surgeons, minimally-invasive surgery specialists, and hospital surgical departments seeking to improve hysterectomy outcomes, reduce patient recovery time, and minimize complications associated with tissue extraction and specimen containment.

Levita Magnetics International Corp. is a medical device company specializing in magnetic surgical technology for minimally invasive procedures. The company's flagship product, MARS™ (Magnetic Autonomously Retractable System), is a first-of-its-kind robotic surgical platform that leverages magnetic technology to enhance precision and accessibility in surgical care. MARS has received FDA clearance and represents a novel approach to minimally invasive surgery by harnessing magnetic and robotic mechanisms. The platform has been deployed in commercial surgical cases and recent applications include AI-guided autonomous surgical camera systems that enhance procedural precision and efficiency. Levita Magnetics markets its technology to hospitals and surgical centers seeking to expand minimally invasive surgical capabilities and improve patient outcomes through advanced magnetic surgery techniques. The company emphasizes patient accessibility and the reduction of surgical invasiveness as core mission drivers.

Renata Medical is a MedTech startup headquartered in Newport Beach, California, specializing in minimally invasive medical devices for pediatric cardiology. Founded in 2019, the company develops innovative solutions to address unmet clinical needs in congenital heart disease and pediatric vascular stenosis. The flagship product, Minima Growth Stent System, is the first and only FDA-approved stent designed specifically for infants weighing over 1.5 kg. This breakthrough device features a gradual re-expansion mechanism that accommodates a child's growth from infancy through adulthood, eliminating the need for multiple interventional procedures. Minima represents a transcatheter alternative to traditional open-heart surgery, reducing operative burden while improving long-term outcomes in the neonatal and pediatric population. Renata Medical's leadership comprises experienced professionals with deep expertise in transcatheter devices and pediatric cardiology, ensuring clinically relevant product development and market deployment strategies.

Astura Medical is a surgeon-inspired medical device manufacturer specializing in minimally invasive spinal fixation systems. The company develops modular posterior spinal fusion and fixation solutions designed for orthopedic and spine surgeries. Their flagship product, Masada MIS, is a modular minimally invasive posterior spinal fixation system engineered to support complex spinal procedures with reduced surgical trauma and improved patient outcomes. Astura Medical is headquartered in Irving, Texas, and operates with a quality-driven, surgeon-centric design philosophy. The company serves orthopedic surgeons, spine specialists, and surgical centers with innovative MIS (minimally invasive surgery) technology for spinal stabilization and fusion procedures.

Praxis Medical LLC is a medical device company headquartered in Tampa, Florida, specializing in motorized, rotating fine needle biopsy systems. The company develops innovative, minimally invasive biopsy devices designed to improve diagnostic outcomes in soft tissue and pulmonary sampling. Their primary product lines include CytoCore, a percutaneous soft tissue biopsy system for radiology applications, and EndoCore, an endobronchial ultrasound (EBUS)-guided biopsy device for pulmonology. Both systems utilize proprietary rotary needle technology that enables collection of core-comparable tissue samples in fewer needle passes compared to standard fine needle aspiration (FNA) techniques. The devices employ non-firing needle mechanisms to prioritize patient safety while maintaining high specimen quality for diagnosis and disease staging. Praxis Medical targets interventional radiologists, pulmonologists, and diagnostic specialists in hospital and outpatient surgical settings. The company emphasizes minimally invasive approaches, reduced procedural passes, improved diagnostic yield, and enhanced patient outcomes as key differentiators. Manufacturing and regulatory status information is not detailed on the website; clinical validation and regulatory pathway details are not explicitly stated.

Forma Medical designs and manufactures minimally invasive surgical implants and instruments for forefoot and midfoot orthopedic procedures. The company specializes in MTP (metatarsophalangeal) joint fusion and Lapidus procedures, offering surgeons comprehensive surgical solutions that prioritize patient outcomes, reduced surgical trauma, and procedural efficiency. Their product portfolio emphasizes maximum stability, minimal incision techniques, and enhanced operative efficiency. Forma Medical serves orthopedic surgeons and podiatric surgeons performing forefoot corrections and joint fusion procedures. The company is located in Hummelstown, Pennsylvania, and focuses on advanced orthopedic implant design with attention to biomechanics and material science to address limitations of existing devices. Their approach targets patients seeking high-quality outcomes with reduced surgical burden and faster recovery timelines.

JENOPTIK is a global photonics technology group headquartered in Jena, Germany, with approximately 4,500 employees and €1.12 billion in annual revenue (FY 2024). The company specializes in optics, lasers, sensors, and integrated photonic systems serving medical technology, semiconductor manufacturing, metrology, and smart mobility sectors. JENOPTIK operates a high-tech manufacturing facility in Dresden producing micro-optics for semiconductor equipment. Key subsidiaries Aesculap-Meditec and TRIOPTICS expand its specialized medical and precision optics offerings. The company provides comprehensive photonic solutions including micro-optical components, laser systems for industrial applications, vision and imaging technologies for life sciences and diagnostics, and automated manufacturing systems. JENOPTIK is listed on the SDAX and TecDAX exchanges.

Schivo is a vertically integrated contract manufacturer specializing in high-quality medical device components, sub-assemblies, and final assemblies for minimally invasive surgical systems, robotic-assisted surgical platforms, cardiovascular and neurovascular devices, and orthopedic implants. The company operates globally with best-practice manufacturing facilities and applies design-for-manufacturability principles to optimize cost, productivity, and time-to-market for OEM partners. Schivo's AFP division manufactures ultra-reliable fluid control components and sub-assemblies for laboratory chromatography instruments, genomic analysis systems, and clinical diagnostic platforms. The company provides full contract manufacturing services including new product introduction (NPI) with early-stage design-to-manufacturing integration, process qualification and validation using ISO-qualified methodologies, and comprehensive regulatory support for FDA submissions. All manufacturing processes are tracked and documented through the company's manufacturing management platform. Schivo is FDA-registered and complies with FDA quality system requirements and ISO standards. The company serves global medical device OEMs across surgical, diagnostic, and life science markets, offering value-added services that extend beyond component manufacturing to include design optimization, risk mitigation, and supply chain integration.

Vycor Medical, Inc. operates two distinct business units specializing in neurosurgical and neurotherapeutic solutions. The primary division designs and manufactures neurosurgical medical devices, with the ViewSite Brain Access System (VBAS) as the flagship product—a minimally invasive neurosurgical device that improves access to brain lesions while reducing tissue damage. Clinical evidence from over 50 studies demonstrates VBAS results in reduced brain tissue trauma, minimized invasiveness, improved surgical visibility, and shortened operating and recovery times. The company's secondary business unit, NovaVision, develops non-invasive, computer-based vision rehabilitation therapies for patients with vision loss resulting from neurological trauma such as stroke. NovaVision Visual Restoration Therapy (VRT) is the only FDA-cleared therapy for vision rehabilitation following neurological brain damage; it is complemented by the NeuroEyeCoach program, which trains patients to make improved eye movements to enhance visual field detection. Vycor Medical serves neurosurgeons, neurologists, rehabilitation specialists, and vision care providers across hospital and outpatient settings. The company holds FDA regulatory clearance for its therapeutic products and demonstrates commitment to clinical validation and evidence-based outcomes.

Monteris Medical Corp is a leader in minimally invasive laser ablation technology for neurosurgical applications. The company specializes in laser interstitial thermal therapy (LITT) systems designed specifically for brain procedures. Their flagship product, the NeuroBlate System, is an MR-guided robotic laser ablation platform indicated for treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. The system represents the only robotic MR-guided laser ablation tool in its class, delivering real-time thermal imaging and precision ablation capabilities for neurosurgical oncology and epilepsy applications. Monteris is committed to prospective multi-center clinical evidence generation, including participation in landmark studies such as LAANTERN to establish the safety and efficacy profile of LITT in brain applications. The company serves neurosurgical centers, academic medical centers, and specialized treatment facilities performing minimally invasive brain procedures. Products are designed for use in intraoperative MRI environments with integrated navigation and thermal monitoring. The company maintains a collaborative, innovation-focused organizational structure supporting product development and clinical evidence generation for minimally invasive neuroablation.

ATEC Spine (Alphatec Holdings, Inc.) is a spinal surgery device manufacturer specializing in innovative interbody fusion systems and surgical technologies. The company develops porous titanium interbody spacers, including the IdentiTi II LIF platform, designed for anterior and posterior spinal fusion procedures. ATEC's product portfolio encompasses procedural technologies across multiple spine surgery approaches: anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), posterior cervical fusion (PCF), lateral transpsoas (LTP), prone transpsoas (PTP), posterior lumbar interbody fusion (PLIF), posterior fixation, and corpectomy. The company positions itself as a revolutionizer of spine surgery approaches with intentional, integrated, and individualized design principles. ATEC Spine serves spine surgeons and hospitals performing complex spinal procedures, competing in the orthopedic implant and minimally invasive spine surgery segment. The company reported full-year 2025 total revenue of $764 million with 25% growth, demonstrating significant market presence. ATEC maintains an active presence at major spine surgery societies and regional symposia, engaging surgeons on procedural innovation and clinical outcomes. The company emphasizes surgeon-driven education, data-informed decision-making, and procedural discipline in spinal fusion techniques.

SPIWay, LLC is a medical device company specializing in access technologies and surgical visualization systems for minimally invasive neurosurgery. The company develops the SPIWAY EAG (Endonasal Assisted Glioma) Platform, a technology designed to improve surgical visualization during endoscopic endonasal approaches (EEA) for neurosurgical procedures. The platform integrates advanced visualization capabilities to support surgeons performing minimally invasive intracranial interventions. SPIWay markets the EAG Platform to neurosurgery departments and specialized surgical centers. The company provides clinical evidence and training resources to support adoption and proper utilization of their technology. While specific regulatory certifications are not mentioned in the available website content, the company operates as a medical device manufacturer serving the neurosurgical market.

Amsel Medical Corporation develops minimally invasive surgical occlusion devices for vessel and tubular structure closure. The company's primary product, SCureClamp™ with Interdigitation Occlusion Technology (iDOT™), is a mechanical surgical clamping device FDA-cleared and CE-marked for closing blood vessels, arteries, veins, and ducts during surgical and interventional procedures. The device employs a unique transfixing mechanism delivered through an 18-gauge needle, providing permanent, non-chemical, non-thermal occlusion similar to hand-sewn transfixion sutures. Key design features include anchoring technology to prevent slippage, accommodation of vessels 2.0–7.0 mm in diameter, and ultrasound-guided deployment. Amsel's SCureClamp targets multiple surgical specialties including vascular surgery, general surgery (bariatric, cardiac, oncology), trauma management, and interventional radiology. In vascular applications, the device addresses limitations of current perforator treatments (lasers, RF, glue, sclerotherapy), which average 75–80% efficacy and lack permanent solutions. Clinical evidence from peer-reviewed publications in the Journal of Vascular Surgery, Surgical Endoscopy, and Journal of Surgical Research demonstrates preclinical efficacy in porcine models. The company is also developing a temporary clamping variant for military trauma applications, specifically targeting non-compressible and junctional hemorrhage in prehospital environments. Amsel Medical was awarded a prestigious U.S. Air Force AFWERX Phase 2 SBIR grant for this development. The company's devices are indicated for use by vein physicians, general surgeons, vascular surgeons, cardiovascular surgeons, interventional radiologists, and military medical personnel. Manufacturing and regulatory compliance align with FDA 510(k) and CE Mark standards.

Bimini Health Tech is a medical device company specializing in reconstructive, aesthetic, and orthopedic solutions, with operations in 50+ countries serving 1.5M+ procedures annually. The company develops advanced technologies focused on women's health, particularly breast reconstruction and fat transfer procedures. Core product portfolio includes: PureGraft®, a proprietary adipose filtration system for harvesting and transferring fat grafts in reconstructive and aesthetic surgery; Essence ADM™, a sterile, ready-to-use acellular dermal matrix available in multiple sizes for plastic and reconstructive procedures; Serene™ Structured Saline Breast Implant, designed to provide silicone-like natural appearance and feel; Dermapose®, an office-based system for standardizing micro fat harvesting, purification, and injection as an alternative to synthetic dermal fillers; and Boost Micronizers for adipose tissue processing. Applications span reconstructive and aesthetic surgery, minimally invasive procedures, and orthopedic/sports medicine utilizing autologous adipose tissue and blood products. The company partners with leading physicians and maintains partnerships with major distributors including Arthrex, Genesis Biologics, GC Aesthetics, Bausch Health, and Crown Aesthetics. Bimini emphasizes scientific rigor, reproducibility, and clinical efficacy in product design and clinical applications.

Retropsoas Technologies, LLC is a medical device company based in Frontenac, Missouri, specializing in minimally invasive spinal fusion solutions. The company has developed the EARP™ (Endoscopic Assisted Retro Psoas) Approach, a proprietary technique for lumbar interbody fusion that combines endoscopic visualization with a posterior mini-open approach. The EARP™ system is FDA 510(k) cleared and addresses limitations of traditional interbody fusion methods by enabling decompression, fusion, and instrumentation at all lumbar levels through a single mini-open incision. Key technical features include a large implant footprint designed to maximize endplate coverage, disc height restoration, and lordosis correction. The system incorporates proprietary intraoperative neuromonitoring (IONM) technology to reduce nerve injury risk to the lumbar plexus during posterior approach procedures. The EARP™ Approach combines strengths of multiple fusion techniques—anterior, lateral, and posterior approaches—into a single minimally invasive solution while reducing complication risks and optimizing fusion potential through direct visualization of the fusion bed. The company targets spine surgeons and surgical centers performing lumbar fusion procedures. Manufacturing and regulatory capabilities include FDA 510(k) clearance, indicating the device meets substantial equivalence standards for market distribution in the United States.

Rex Medical LP is a medical device manufacturer specializing in minimally invasive solutions for cardiovascular, venous access, endosurgery, and oncology applications. The company develops and markets innovative devices designed to address unmet clinical needs in these therapeutic areas. Their primary product offering includes the REVOLUTION™ Peripheral Atherectomy System, a device used for peripheral vascular intervention. Rex Medical is ISO 13485 certified, indicating compliance with medical device quality management system standards. The company focuses on delivering high-quality patient care through technology-driven innovation in the minimally invasive medical device sector.

PEAK Medical Distribution Inc. is a wholesale distributor of surgical and medical instruments, apparatus, and equipment, founded in 2009. The company specializes in representation and distribution of cardiac, thoracic, and vascular medical device manufacturers, serving North America. PEAK functions as both a distributor and contract manufacturer, offering instrumentation, equipment, and integrated surgical platforms designed for cardiac, thoracic, and vascular surgery procedures. The company provides products and customization options across large incision, minimally invasive, robotic, and catheter-based surgical technologies. PEAK maintains a team of highly trained sales representatives and customer service professionals dedicated to addressing client needs. The company emphasizes engineering and design consultation to tailor solutions for surgeon-specific requirements. While the fetched content does not explicitly list regulatory certifications or detailed product models, PEAK positions itself as a distributor of state-of-the-art, high-quality medical devices aligned with global manufacturing standards.

HK Surgical is a leader in the development, distribution, and marketing of liposuction and fat harvesting/grafting surgical supplies, founded in 1998 by Dr. Jeffrey Klein. The company specializes in equipment and supplies for tumescent local anesthesia procedures, including the proprietary Klein Infiltration Pump (available in multiple models: KIP-II+, KTDD). HK Surgical offers a comprehensive product portfolio encompassing infiltration and aspiration pumps, surgical cannulas (reusable and single-use), fat collection and transfer systems, infiltration tubing sets, positioning pillows, super-absorbent surgical pads, OR table sheets, compression garments, and catheter sets. The company serves plastic surgeons, physicians, nurses, and patients, emphasizing superior quality, reliability, and value. Products are FDA-approved and designed for liposuction, body contouring, varicose vein ablation, and facial procedures. HK Surgical provides same-day shipping on orders placed by 1 PM PST and offers live customer support.

BoneBac manufactures minimally invasive surgical devices for bone graft collection and processing during orthopedic procedures. The company's primary product, the BoneBac Press, is a single-use, pre-sterilized device that enables surgeons to harvest, collect, and process autologous bone from the surgical site during fusion procedures. This technology reduces reliance on allograft bone substitutes and synthetic bone alternatives, potentially lowering per-surgery costs by over 80% while increasing the volume of available bone for fusion applications. The device is designed to streamline intraoperative bone collection and processing, minimizing operative time and eliminating the need for secondary donor site harvesting. BoneBac has been manufacturing medical devices in the United States since 2011 and is based in Sandown, New Hampshire. The company holds FDA registration and ISO 13485:2016 certification, indicating compliance with medical device manufacturing and quality management standards. Products are currently marketed and sold within the United States only.

CORONEO Inc. is a Canadian medical device manufacturer specializing in innovative cardiac surgery solutions since 1997. The company designs and manufactures high-precision surgical instruments and implants for minimally invasive aortic valve repair and coronary artery stabilization. CORONEO's flagship product, the EXTRA-AORTIC Ring, is the market-leading external annuloplasty device for aortic valve repair, with over 2,500 successful implants globally. The company also produces the COR-VALV System (adjustable tissue retractors), COR-VASC System (reusable stabilization platform for beating heart bypass), PEDIATRIC Retractors (titanium retractors for pediatric cardiac surgery), and SWIFT-LOOP Vessel Loops (atraumatic vessel occlusion devices). All products are fabricated from premium titanium alloys and certified ISO 13485:2016, with regulatory approvals including CE Mark, FDA, and Health Canada. CORONEO maintains in-house prototype facilities, plastic injection molding, and clean room capabilities, enabling rapid design iteration and medium-volume production. The company serves hospitals and surgical centers across North America, Europe, and Asia through a dedicated distributor network.

Expanding Innovations, Inc. (EI) designs and manufactures next-generation expandable interbody fusion cage systems for spinal surgery. The company specializes in non-screw-based expandable cage technology designed to address post-operative vertebral body subsidence and cage collapse—critical complications in minimally invasive lumbar fusion procedures. EI's X-PAC® product line comprises the X-PAC TLIF (transforaminal lumbar interbody fusion), X-PAC LLIF (lateral lumbar interbody fusion), and X-PAC N-GAGE lumbar plate system with modular coupling. The X-PAC technology relocates the lifting mechanism from within the cage to the inserter instrument, enhancing expansion control, tactile feedback, and adaptability to individual patient bone quality. All systems feature unidirectional locking teeth for controlled expansion and open architecture supporting post-operative bone packing. EI's devices are indicated for addressing degenerative spine conditions, particularly in aging populations where bone quality is compromised. The company markets to spine surgeons and surgical centers performing minimally invasive and open spinal fusion procedures. Regulatory status and specific certifications (FDA 510(k), ISO 13485) are not detailed on the fetched content.

Deep Blue Medical Advances develops next-generation surgical devices focused on soft tissue surgery and hernia repair. The company's core portfolio includes the T-Line® Hernia Mesh, a novel mesh system designed to address common failure modes in hernia repair, particularly suture pull-through and tissue dehiscence. The T-Line® Hernia Mesh is currently in use in surgical suites across the United States and targets the $1.1 billion global hernia device market. The company is also developing the T-Line® TCS (Tissue Control Suture) for general soft tissue procedures, intended to improve procedure speed, safety, and durability while reducing patient pain from tissue trauma. Additional products under development include the T-Line® Scaffold for breast surgery applications and an Anchor Clip for simplified mesh implantation. The company offers both investigational and commercial-stage devices and is pursuing variants including biosynthetic and coated composite versions of their hernia mesh platform. Deep Blue has been recognized with the 2024 Luis Villalobos Award for Innovative Company of the Year in Life Sciences, indicating clinical and market validation of their surgical technology approach.

NovApproach Spine develops innovative solutions for anterior lumbar interbody fusion (ALIF) surgery, specifically designed to simplify surgical approaches and improve patient outcomes. The company's flagship product is the OneLIF™ cage system, a patented interbody implant engineered for single-position anterior lumbar spine surgery. The OneLIF device features a unique design allowing trials and implants to be inserted in both straight and oblique directions with lateral screw fixation from the left side, minimizing soft tissue retraction and vascular exposure compared to traditional ALIF approaches. The system is designed to accommodate a wide range of anatomies while reducing the need for extensive surgical exposure. NovApproach Spine collaborates with leading academic spine surgeons and spinal access surgeons to develop both surgical approaches and corresponding implants that represent advances in lumbar implant versatility. The company emphasizes efficiency, versatility, and surgeon collaboration as core differentiators. Products are marketed toward spine specialists, neurosurgeons, and orthopedic surgeons performing anterior lumbar reconstruction procedures. The technology is positioned as addressing key limitations of traditional ALIF techniques, particularly for cases with limited exposure or complex vascular/neural anatomy. While specific FDA clearance or regulatory credentials are not detailed on the fetched site, the company's focus on surgical innovation and implant design suggests compliance with orthopedic device regulations.

Biorep Technologies is an ISO 13485-certified, FDA-registered medical device contract design and manufacturing organization (CDMO) based in Miami Lakes, Florida. Founded in 1994, the company specializes in end-to-end medical device development and manufacturing services, including rapid prototyping, design verification, process development and validation, contract manufacturing, and assembly services. With over 30 years of experience, Biorep serves medical device companies across cardiovascular, minimally invasive surgical instruments, ENT devices, and diabetes research equipment sectors. The company maintains a vertically integrated structure with capabilities spanning concept through scale-up, production launch, and lifecycle support. Biorep partners with global med-tech innovators and maintains a strategic partnership with the Diabetes Research Institute, providing essential research equipment for type I diabetes initiatives. The company operates with documented design controls, traceability systems, supply chain management, and regulatory compliance infrastructure compatible with US, EU, and Asian markets.

HMDmd develops wearable surgical display technology designed to enhance visualization and ergonomics in minimally invasive surgery. The company's CR3 Wearable Surgical Monitor provides surgeons with high-fidelity color imaging and natural 3D visualization without polarizer distortion, improving depth perception in both 2D and 3D surgical environments. The device connects to standard imaging platforms and is engineered to reduce surgeon fatigue while maintaining situational awareness during complex procedures. HMDmd serves surgical teams seeking advanced visualization tools for challenging intraoperative scenarios, positioning itself as a purpose-built solution for enhanced surgical vision and ergonomic positioning.

Nutek Orthopaedics manufactures advanced minimally-invasive external fixation systems for orthopedic surgery, leveraging over 50 years of surgeon-informed design experience. Their proprietary technology features axial freedom for precision K-wire placement, spherical pin-locking mechanisms, and radiolucent Ultem® plates enabling real-time fluoroscopic visualization. Products address shoulder, wrist, hand, and general orthopedic trauma applications. The systems prioritize reduced operative time, low infection rates, preserved vascularity, minimal soft-tissue damage, and early patient mobility without permanent implants—enabling rapid return to normal function.